CLAIMS:

What we claim is :-

1. A compound of formula (1):



formula (1)

Z is selected from $-CONR^{15}OH$ and $-N(OH)CHO$;

R^{15} is hydrogen or C_{1-3}alkyl;

R^1 is hydrogen or a group selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-7}cycloalkyl, C_{5-7}cycloalkenyl, aryl and heteroaryl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethyloxy, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl (optionally substituted by one or more R^{17}), aryl (optionally substituted by one or more R^{17}), heteroaryl (optionally substituted by one or more R^{17}), heterocyclyl, C_{1-4}alkoxycarbonyl, $-OR^5$, $-SR^2$, $-SOR^2$, $-SO_2R^2$, $-COR^2$, $-CO_2R^5$, $-CONR^5R^6$, $-NR^{16}COR^5$, $-SO_2NR^5R^6$ and $-NR^{16}SO_2R^2$;

R^{16} is hydrogen or C_{1-3}alkyl;

R^{17} is selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, C_{1-6}alkyl, C_{3-6}cycloalkyl and C_{1-6}alkoxy;

R^2 is group selected from C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{5-7}cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, arylC_{1-4}alkyl and heteroarylC_{1-4}alkyl where the group is optionally substituted by one or more halo;

R^5 is hydrogen or a group selected from C_{1-6}alkyl, C_{3-6}cycloalkyl, C_{5-7}cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, arylC_{1-4}alkyl and heteroarylC_{1-4}alkyl where the group is optionally substituted by one or more halo;

R^6 is hydrogen, C_{1-6}alkyl or C_{3-6}cycloalkyl;

or R^5 and R^6 together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

R^8 is hydrogen or a group selected from C_{1-6}alkyl, C_{3-7}cycloalkyl and C_{5-7}cycloalkenyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethyloxy and C_{1-4}alkyl;

R^3 and R^4 are both hydrogen;

n is 0 or 1;

m is 0 or 1;

D is hydrogen, C_{1-4}alkyl, C_{3-6}cycloalkyl or fluoro;

X is $-(CR^9R^{10})_t-Q-(CR^{11}R^{12})_u-$ where t and u are independently 0 or 1 with the proviso that t and u cannot both be 0;

Q is O, S, SO or SO_2;

R^9, R^{10}, $R^{11}$and R^{12} are independently selected from hydrogen, C_{1-4}alkyl and C_{3-6}cycloalkyl;

B is a group selected from aryl, heteroaryl, heterocyclyl, C_{3-10}cycloalkyl and C_{5-7}cycloalkenyl where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethyloxy, halo, C_{1-4}alkyl (optionally substituted by one or more R^{13}), C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl (optionally substituted by one or more R^{13}), heterocycloalkyl, heteroaryl, aryl, $-OR^{13}$, cyano, $-NR^{13}R^{14}$, $-CONR^{13}R^{14}$, $-NR^{16}COR^{13}$, $-SO_2NR^{13}R^{14}$, $-NR^{16}SO_2R^{13}$, $-SR^{13}$, $-SOR^7$ and $-SO_2R^7$;

R^7 is C_{1-6}alkyl or C_{3-6}cycloalkyl

R^{13} and R^{14} are independently hydrogen, C_{1-6}alkyl or C_{3-6}cycloalkyl;

or R^{13} and R^{14} together with the nitrogen to which they are attached form a heterocyclic 4 to 7-membered ring.

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

2. A compound according to claim 1 wherein X is $-(CH_2)-O-$, $-O-(CH_2)-$, $-(CH_2)-O-(CH_2)-$ or $-(CHMe)-O-$.

3. A compound according to claim 1 or 2 wherein R^1 is C_{1-4}alkyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl, aryl, heteroaryl and C_{1-4}alkyl substituted by aryl or heteroaryl wherein any R^1 group is optionally substituted by one or more substitutents independently selected from halo, cyano, nitro, C_{1-4}alkoxy, C_{1-4}alkyl, trifluoromethyl and trifluoromethoxy.

4. A compound according to any one of claims 1 to 3 wherein B is a group selected from aryl, heteroaryl, heterocyclyl, C_{3-10}cycloalkyl and C_{5-7}cycloalkenyl where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, halo, C_{1-4}alkyl, heteroaryl, $-OR^{13}$, cyano, $-NR^{13}R^{14}$, $-CONR^{13}R^{14}$ and $-NR^{16}COR^{13}$.

5. A compound according to claim 4 wherein B is aryl, heteroaryl or C_{3-6}cycloalkyl optionally substituted by 1, 2 or 3 groups independently selected from C_{1-4}alkyl, halo, cyano, nitro, C_{1-4}alkoxy and trifluoromethyl

6. A compound according claim 5 wherein B is 2,5-dimethylphenyl or 2-methylquinolin-4-yl.

7. A compound according to claim 1, selected from:

(R/S)-1-[({4-[(2-methylquinolin-4-yl)methyloxy]piperidin-1-yl}sulphonyl)methyl]-4-pyrimidin-2-ylbutyl(hydroxy)formamide;

(R/S)-1-methyl-2-({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)ethyl(hydroxy)formamide;

(R/S)-1-pyrid-3-yl-2-({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)ethyl(hydroxy)formamide;

(R/S)-1-(1*H*-imidazol-4-yl)-2-({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)ethyl(hydroxy)formamide;

(R/S)-2-({4-[(2,5-dimethylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyrid-3-ylethyl(hydroxy)formamide;

(R/S)-[1-({[4-(2,5-dimethylbenzyloxy)piperidin-1-yl]sulphonyl}methyl)-3-phenylpropyl]hydroxyformamide;

(R/S)-2-({4-[(2,5-dimethylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-[4-fluoro-2-(trifluoromethyl)phenyl]ethyl(hydroxy)formamide;

(R/S)-2-({4-[(2,5-dimethylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-[2-(trifluoromethyl)phenyl]ethyl(hydroxy)formamide;

(R/S)-2-({4-[(2,5-dimethylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-[3-(trifluoromethyl)phenyl]ethyl(hydroxy)formamide;

(R/S)-2-({4-[(2,5-dimethylphenoxy)methyl]piperidin-1-yl}sulphonyl)-1-(4-fluorophenyl)ethyl(hydroxy)formamide;

(R/S)-1-{[(4-{[(2,5-dimethylbenzyl)oxy]methyl}piperidin-1-yl)sulphonyl]methyl}-4-pyrimidin-2-ylbutyl(hydroxy)formamide

(R/S)-2-methyl-3-({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)propionic hydroxamic acid

(R/S)-2-({4-[(2,5-difluorobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide

(R/S)-hydroxy(1-phenyl-2-{[4-(pyridin-2-ylmethoxy)piperidin-1-yl]sulphonyl}ethyl)formamide;

(R/S)-hydroxy(1-phenyl-2-{[4-(pyridin-3-ylmethoxy)piperidin-1-yl]sulphonyl}ethyl)formamide;

(R/S)-2-({4-[(2,6-difluoro-3-methylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide;

(R/S)-2-({4-[(2-chloro-6-fluorobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide;

(R/S)-2-({4-[(5-fluoro-2-methylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide;

(R/S)-2-{[4-(benzyloxy)piperidin-1-yl]sulphonyl}-1-phenylethyl(hydroxy)formamide;

(R/S)-hydroxy[2-({4-[(2-methylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl]formamide;

(R/S)-2-({4-[(3-chlorobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide;

(R/S)-2-({4-[(2-bromobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide;

(R/S)-2-({4-[(2-fluorobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide;

(R/S)-2-({4-[(2,6-difluorobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide;

(R/S)-2-({4-[(3-fluorobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide;

(R/S)-hydroxy{1-phenyl-2-[(4-{[4-(trifluoromethyl)benzyl]oxy}piperidin-1-yl)sulphonyl]ethyl}formamide;

(R/S)-2-{[4-(cyclohexylmethoxy)piperidin-1-yl]sulphonyl}-1-phenylethyl(hydroxy)formamide;

(R/S)-2-({4-[(4-bromobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide;

(R/S)-2-({4-[(4-fluorobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide;

(R/S)-2-({4-[(2,5-dimethylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide;

(R/S)-2-({4-[(2-fluoro-3-methylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-phenylethyl(hydroxy)formamide;

(R/S)-hydroxy[2-({4-[(2-methylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl]formamide;

(R/S)-hydroxy[2-({4-[(4-methylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl]formamide;

(R/S)-2-({4-[(2-fluorobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide;

(R/S)-2-({4-[(2-chlorobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide;

(R/S)-2-({4-[(2,4-dichlorobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide;

(R/S)-2-({4-[(2,6-dichlorobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide;

(R/S)-hydroxy(2-{[4-(mesitylmethoxy)piperidin-1-yl]sulphonyl}-1-pyridin-3-ylethyl)formamide;

(R/S)-2-({4-[(3,4-dichlorobenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide;

(R/S)-hydroxy[2-({4-[(3-methoxybenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl]formamide;

(R/S)-hydroxy[2-({4-[(3-methylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl]formamide;

(R/S)-2-({4-[(3,4-dimethylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide;

(R/S)-hydroxy[2-({4-[(4-methoxybenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl]formamide;

(R/S)-hydroxy[2-({4-[(4-isopropylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl]formamide;

(R/S)-2-({4-[(3-chloro-4-methylbenzyl)oxy]piperidin-1-yl}sulphonyl)-1-pyridin-3-ylethyl(hydroxy)formamide;

(R/S)-N-hydroxy-N-isopropyl-2-methyl-3-({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)propanamide;

hydroxy{(1R)-1-[({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)methyl]-4-pyrimidin-2-ylbutyl}formamide;

hydroxy{(1S)-1-[({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)methyl]-4-pyrimidin-2-ylbutyl}formamide;

(2R)-N-hydroxy-2-methyl-3-({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)propanamide

(R/S)-2-cyclopentyl-N-hydroxy-3-({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)propanamide;

(2S)-2-cyclopentyl-N-hydroxy-3-({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)propanamide;

(2R)-2-cyclopentyl-N-hydroxy-3-({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)propanamide;

(2S)-N-hydroxy-4-methyl-2-[({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)methyl]pentanamide;

(2R)-N-hydroxy-4-methyl-2-[({4-[(2-methylquinolin-4-yl)methoxy]piperidin-1-yl}sulphonyl)methyl]pentanamide; and

(R/S)-*N*-{1-[4-(2,6-dimethyl-pyridin-4-ylmethoxy)-piperidine-1-sulphonylmethyl]-4-pyrimidin-2-yl-butyl}-*N*-(hydroxy)formamide.

8. A compound according to claim 1 for use as a medicament.

9. The use of a compound according to claim 1 in the manufacture of a medicament in the treatment of a disease condition mediated by one or more metalloproteinase enzymes.

10. The use of a compound according to claim 1 in the manufacture of a medicament in the treatment of a disease condition mediated TNFα.

11. A method of treating autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound accoding to claim 1.

12. A pharmaceutical composition comprising a compound according to claim 1; and a pharmaceutically-acceptable diluent or carrier.

13. A process for preparing a compound according to claim 1 which comprises;

when Z is –N(OH)CHO, the step of:

a) converting a hydroxylamine of formula (2) into a compound of formula (1);



formula (2) formula (1)

or where Z is –CONR^{15}OH the step of;

b) converting an acid of formula (14) into a compound of formula (1);



formula (14) formula (1)

and thereafter if necessary:

i) converting a compound of formula (1) into another compound of formula (1);

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

5